GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Vaso Corporation (OTCPK:VASO) » Definitions » ROE %

Vaso (VASO) ROE % : 16.49% (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Vaso ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Vaso's annualized net income for the quarter that ended in Dec. 2023 was $4.32 Mil. Vaso's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $26.23 Mil. Therefore, Vaso's annualized ROE % for the quarter that ended in Dec. 2023 was 16.49%.

The historical rank and industry rank for Vaso's ROE % or its related term are showing as below:

VASO' s ROE % Range Over the Past 10 Years
Min: -50.59   Med: 11.75   Max: 74.41
Current: 19.52

During the past 13 years, Vaso's highest ROE % was 74.41%. The lowest was -50.59%. And the median was 11.75%.

VASO's ROE % is ranked better than
85.95% of 612 companies
in the Healthcare Providers & Services industry
Industry Median: 4.035 vs VASO: 19.52

Vaso ROE % Historical Data

The historical data trend for Vaso's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaso ROE % Chart

Vaso Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.70 7.62 74.41 67.68 19.65

Vaso Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 175.44 8.00 34.11 18.85 16.49

Competitive Comparison of Vaso's ROE %

For the Health Information Services subindustry, Vaso's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaso's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Vaso's ROE % distribution charts can be found below:

* The bar in red indicates where Vaso's ROE % falls into.



Vaso ROE % Calculation

Vaso's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=4.805/( (22.067+26.843)/ 2 )
=4.805/24.455
=19.65 %

Vaso's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=4.324/( (25.609+26.843)/ 2 )
=4.324/26.226
=16.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Vaso  (OTCPK:VASO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=4.324/26.226
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(4.324 / 87.668)*(87.668 / 74.3975)*(74.3975 / 26.226)
=Net Margin %*Asset Turnover*Equity Multiplier
=4.93 %*1.1784*2.8368
=ROA %*Equity Multiplier
=5.81 %*2.8368
=16.49 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=4.324/26.226
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (4.324 / 4.584) * (4.584 / 3.88) * (3.88 / 87.668) * (87.668 / 74.3975) * (74.3975 / 26.226)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9433 * 1.1814 * 4.43 % * 1.1784 * 2.8368
=16.49 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Vaso ROE % Related Terms

Thank you for viewing the detailed overview of Vaso's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaso (VASO) Business Description

Traded in Other Exchanges
N/A
Address
137 Commercial Street, Unit 200, Plainview, NY, USA, 11803
Vaso Corporation is a medical technology company. It provides diverse product and service categories, including noninvasive monitoring and therapeutic devices, diagnostic imaging equipment, and information technology for enterprises and clinical customers. The company currently operates in three distinct business units namely IT; Professional sales and Equipment. It generates maximum revenue from the IT segment. IT segment focuses on healthcare IT and managed network technology services.
Executives
Leon Dembo director 137 COMMERCIAL STREET, SUITE 200, PLAINVIEW NY 11803
Janey Moen director 137 COMMERCIAL STREET, SUITE 200, PLAINVIEW NY 11803
Jun Ma director C/O VASOMEDICAL, INC., 180 LINDEN AVENUE, WESTBURY NY 11590
Edgar Rios director 1650 TYSONS BOULEVARD, SUITE 900, MCLEAN VA 22102
Michael Beecher officer: Chief Financial Officer C/O DIRECT INSITE CORP, 80 ORVILLE DRIVE, BOHEMIA NY 11716
Joshua Markowitz director 3131 PRINCETON PIKE, BLDG. 3D, SUITE 200, LAWRENCEVILLE NJ 08648
Jonathan P Newton officer: Vice Pres Finance & Controller 152 RICHMOND AVENUE, AMITYVILLE NY 11701
Peter C Castle director C/O NETWOLVES CORP, 4002 EISENHOWER BLVD, TEMPA FL 33634
David H Lieberman director 3061 INDUSTRY DR, LANCASTER PA 17603
Behnam Movaseghi director C/O KERNS MANUFACTURING CORPORATION, 37-14 29TH STREET, LONG ISLAND CITY NY 11101
Nelson Randall Hill officer: Senior Vice President 3880 EAST COUNTY HIGHWAY 30A, UNIT 201, SANTA ROSA BEACH FL 24159
William Edward Dempsey director 52 PARK AVENUE, SANDYMOUNT L2 DUBLIN 4
David Tarachand Singh officer: Chief Financial Officer C/O VASOMEDICAL, INC., 180 LINDEN AVENUE, WESTBURY NY 11590
Joseph Giacalone director
Derek Enlander director 88C UNION AVENUE, CENTER MORICHES NY 11934